Traditional MedicareCoverageMedium impact
Implantable Continuous Glucose Monitors (I-CGM)
Medicare/CMS - LCD·Endocrinology, Internal Medicine, Family Medicine +1 more·Local Coverage Determination
Effective date
Apr 1, 2026
We identified it
Jul 28, 2026
Summary
Wellpoint Federal (MAC Part A and Part B) issued a new Local Coverage Determination (LCD L38623) for Implantable Continuous Glucose Monitors (I-CGM) effective April 1, 2026. This policy establishes coverage criteria, medical necessity requirements, and billing guidelines for I-CGM devices. Billing teams must review coverage criteria and implement any prior authorization or documentation requirements by the effective date.
Action Required
By March 15, 2026: Billing team must obtain and review the complete LCD L38623 policy text from the CMS Medicare Coverage Database link provided. Identify specific CPT codes, HCPCS codes, and any prior authorization requirements for I-CGM devices. Update billing system rules, encounter templates, and provider documentation requirements accordingly. Coordinate with clinical staff to ensure medical necessity documentation is captured per policy. Flag any claims for I-CGM devices submitted before April 1, 2026 as they may be subject to different coverage rules. Contact Wellpoint Federal directly for clarification on coverage criteria and any special billing instructions not captured in this summary.